Compare Ascendis Pharma A/S (ASND) vs Direxion Daily 20 Year Treasury Bull 3X Shares (TMF) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Direxion Daily 20 Year Treasury Bull 3X Shares — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Direxion Daily 20 Year Treasury Bull 3X Shares trades at $33.27. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, Direxion Daily 20 Year Treasury Bull 3X Shares nearer its low. Which is the better fit depends on your goals.
| ASND | TMF | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $277.18 | $44.14 |
52-Week Low | $163.32 | $31.85 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
TMF trades at $33.42, showing minimal daily movement with a slight decline of 0.06%. The technical outlook is bearish with moving averages signaling strong selling pressure, though oscillators remain neutral. Recent news highlights significant long-term underperformance, with a $10,000 investment five years ago now worth approximately $1,527, emphasizing the leveraged ETF's high-risk nature.
The outlook for TMF remains challenging due to its leveraged structure and bearish technical signals. Investment opportunities exist for short-term traders betting on bond market rebounds, but risks include daily leverage decay, interest rate volatility, and the ETF's unsuitability for long-term holdings. Caution is warranted given the amplified loss potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Direxion Daily 20 Year Treasury Bull 3X Shares
TMF is a leveraged ETF that seeks to provide 300% (3x) of the daily performance of the ICE U.S. Treasury 20+ Year Bond Index. It is a tactical instrument used by sophisticated traders to capitalize on declining interest rates or to hedge against equity market volatility. Due to its daily reset mechanism and high expense ratio, TMF is structurally designed for short-term speculation rather than long-term buy-and-hold investing.
Read more on TMF →
